Journal of liver cancer最新文献

Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report. 门静脉肿瘤血栓形成肝细胞癌患者停用阿特珠单抗-贝伐单抗治疗后的持久完全应答：首次报告。

Journal of liver cancer Pub Date : 2024-11-05 DOI: 10.17998/jlc.2024.09.26

Pramod Kumar, Pradeep Krishna, Rohit Maidur, Naveen Chandrashekhar, Suresh Raghavaiah

引用次数: 0

Superselective ablative chemo-ethanol embolization for recurrent single hepatocellular carcinoma: a 6-month outcome analysis. 超选择性消融化疗乙醇栓塞治疗复发性单肝细胞癌：六个月疗效分析。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-05-14 DOI: 10.17998/jlc.2024.05.08

Jae Hwan Lee, Kun Yung Kim, Chong-Ho Lee, Minuk Kim, Chang Jin Yoon

{"title":"Superselective ablative chemo-ethanol embolization for recurrent single hepatocellular carcinoma: a 6-month outcome analysis.","authors":"Jae Hwan Lee, Kun Yung Kim, Chong-Ho Lee, Minuk Kim, Chang Jin Yoon","doi":"10.17998/jlc.2024.05.08","DOIUrl":"10.17998/jlc.2024.05.08","url":null,"abstract":"Backgrounds/aims: To evaluate the safety and effectiveness of superselective ablative chemo-ethanol embolization (SACE) for the treatment of patients with recurrent single hepatocellular carcinoma (rHCC).Methods: This retrospective study included 22 patients (19 men; median age, 63 years [range, 38-86]) with Child-Pugh class of A/ B/C (16/3/3) that underwent SACE between January and June 2023 for recurrent single HCCs measuring ≤5 cm in diameter using a mixture of 99% ethanol and ethiodized oil/doxorubicin emulsion. The primary endpoint was the 6-month tumor response, and the secondary endpoints were the 1-month tumor response and treatment-related safety. This study was approved by our institutional review board, and the requirement for informed consent was waived.Results: SACE was successfully performed in 22 patients (95.2%). The complete response rates at 1-month and 6-month after treatment were 100.0% and 83.3%, respectively. At 6-month, local tumor progression occurred in one patient and intrahepatic distant metastasis was found in six patients (30.0%). No 6-month mortalities were reported. No adverse events greater than grade 2 or laboratory deteriorations were observed. Biliary complications or liver abscesses were not observed.Conclusions: SACE for a single rHCC was highly effective in achieving a favorable 6-month tumor response and showed acceptable adverse events. However, further prospective studies are required to verify these findings.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"217-223"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140917589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heavy smoking increases early mortality risk in patients with hepatocellular carcinoma after curative treatment. 大量吸烟会增加肝细胞癌患者治愈后的早期死亡风险。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-06-07 DOI: 10.17998/jlc.2024.06.02

Jaejun Lee, Jong Young Choi, Soon Kyu Lee

{"title":"Heavy smoking increases early mortality risk in patients with hepatocellular carcinoma after curative treatment.","authors":"Jaejun Lee, Jong Young Choi, Soon Kyu Lee","doi":"10.17998/jlc.2024.06.02","DOIUrl":"10.17998/jlc.2024.06.02","url":null,"abstract":"Backgrounds/aims: Although cigarette smoking has been associated with an increased risk of hepatocellular carcinoma (HCC), its association with HCC mortality remains underexplored. We aimed to evaluate the effect of smoking on early mortality in HCC patients following curative treatment.Methods: Data from the Korean Primary Liver Cancer Registry were examined for HCC patients who underwent liver resection or radiofrequency ablation between 2015 and 2018. Smoking cumulative dose was assessed in pack-years. The primary outcome was the 3-year overall survival (OS).Results: Among 1,924 patients, 161 were classified as heavy smokers (≥40 pack-years). Heavy smokers exhibited a lower 3-year survival rate (77.1%) than nonsmokers (83.3%), with a significant difference observed in the 3-year OS (P=0.016). The assessment of smoking pack-years in relation to 3-year OS revealed a dose-dependent pattern, with the hazard ratio exceeding 1.0 at 20 pack-years and continuing to rise until 40 pack-years, reaching peak at 1.21 (95% confidence interval, 1.01-1.45). Multivariate Cox-regression analysis revealed heavy smoking, age ≥60 years, underlying cirrhosis, tumor size >3 cm, vascular invasion, and Child-Pugh class B/C as risk factors for 3-year OS. Subgroup analyses of patients with a tumor size <3 cm, absence of vascular invasion, and meeting the Milan criteria also showed inferior outcomes for heavy smokers in all three subgroups.Conclusions: Heavy smoking, defined as a history of >40 pack-years, was linked to poorer 3-year survival outcomes in HCC patients undergoing curative treatments, underscoring the importance of smoking cessation in this population.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"253-262"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141297617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New systemic treatment options for advanced cholangiocarcinoma. 晚期胆管癌的新系统治疗方案。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-08-08 DOI: 10.17998/jlc.2024.08.07

Valentina Zanuso, Giulia Tesini, Elena Valenzi, Lorenza Rimassa

{"title":"New systemic treatment options for advanced cholangiocarcinoma.","authors":"Valentina Zanuso, Giulia Tesini, Elena Valenzi, Lorenza Rimassa","doi":"10.17998/jlc.2024.08.07","DOIUrl":"10.17998/jlc.2024.08.07","url":null,"abstract":"Cholangiocarcinoma (CCA) is a rare and aggressive cancer, mostly diagnosed at advanced or metastatic stage, at which point systemic treatment represents the only therapeutic option. Chemotherapy has been the backbone of advanced CCA treatment. More recently, immunotherapy has changed the therapeutic landscape, as immune checkpoint inhibitors have yielded the first improvement in survival and currently, the addition of either durvalumab or pembrolizumab to standard of care cisplatin plus gemcitabine represents the new first-line treatment option. However, the use of immunotherapy in subsequent lines has not demonstrated its efficacy and therefore, it is not approved, except for pembrolizumab in the selected microsatellite instability-high population. In addition, advances in comprehensive genomic profiling have led to the identification of targetable genetic alterations, such as isocitrate dehydrogenase 1 (IDH1), fibroblast growth factor receptor 2 (FGFR2), human epidermal growth factor receptor 2 (HER2), proto-oncogene B-Raf (BRAF), neurotrophic tropomyosin receptor kinase (NTRK), rearranged during transfection (RET), Kirsten rat sarcoma virus (KRAS), and mouse double minute 2 homolog (MDM2), thus favoring the development of a precision medicine approach in previously treated patients. Despite these advances, the use of molecularly driven agents is limited to a subgroup of patients. This review aims to provide an overview of the newly approved systemic therapies, the ongoing studies, and future research challenges in advanced CCA management.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"155-170"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141904018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the role of liver resection as a first-line treatment option for multinodular BCLC-A hepatocellular carcinoma. 探索肝切除术作为多结节 BCLC-A 型肝癌一线治疗方案的作用。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-08-16 DOI: 10.17998/jlc.2024.08.08

Joo Hyun Oh, Dong Hyun Sinn

引用次数: 0

Recent update of proton beam therapy for hepatocellular carcinoma: a systematic review and meta-analysis. 质子束疗法治疗肝细胞癌的最新进展：系统回顾和荟萃分析。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-07-04 DOI: 10.17998/jlc.2024.06.26

Sun Hyun Bae, Won Il Jang, Hanna Rahbek Mortensen, Britta Weber, Mi Sook Kim, Morten Høyer

{"title":"Recent update of proton beam therapy for hepatocellular carcinoma: a systematic review and meta-analysis.","authors":"Sun Hyun Bae, Won Il Jang, Hanna Rahbek Mortensen, Britta Weber, Mi Sook Kim, Morten Høyer","doi":"10.17998/jlc.2024.06.26","DOIUrl":"10.17998/jlc.2024.06.26","url":null,"abstract":"Backgrounds/aims: Although access to proton beam therapy (PBT) is limited worldwide, its use for the treatment of hepatocellular carcinoma (HCC) is gradually increasing with the expansion of new facilities. Therefore, we conducted a systematic review and metaanalysis to investigate the updated evidence of PBT for HCC.Methods: The MEDLINE, EMBASE, Cochrane Library, and Web of Science databases were systematically searched for studies that enrolled patients with liver-confined HCC that were treated with PBT for a cure up to February 2024.Results: A total of 1,858 HCC patients receiving PBT from 22 studies between 2004 and 2023 were selected for this meta-analysis. The median proportion of Child-Pugh class A was 86% (range, 41-100), and the median tumor size was 3.6 cm (range, 1.2-9.0). The median total dose ranged from 55 GyE to 76 GyE (median, 69). The pooled rates of 3- and 5-year local progression-free survival after PBT were 88% (95% confidence interval [CI], 85-91) and 86% (95% CI, 82-90), respectively. The pooled 3- and 5-year overall rates were 60% (95% CI, 54-66) and 46% (95% CI, 38-54), respectively. The pooled rates of grade 3 hepatic toxicity, classic radiationinduced liver disease (RILD), and non-classic RILD were 1%, 2%, and 1%, respectively.Conclusions: The current study supports PBT for HCC and demonstrates favorable long-term survival and low hepatic toxicities compared with other published studies on other radiotherapy modalities. However, further studies are needed to identify the subgroups that will benefit from PBT.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"286-302"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141500033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolving trends in treatment patterns for hepatocellular carcinoma in Korea from 2008 to 2022: a nationwide population-based study. 2008年至2022年韩国肝细胞癌治疗模式的演变趋势：一项基于全国人口的研究。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-08-26 DOI: 10.17998/jlc.2024.08.13

Ji Won Han, Won Sohn, Gwang Hyeon Choi, Jeong Won Jang, Gi Hyeon Seo, Bo Hyun Kim, Jong Young Choi

{"title":"Evolving trends in treatment patterns for hepatocellular carcinoma in Korea from 2008 to 2022: a nationwide population-based study.","authors":"Ji Won Han, Won Sohn, Gwang Hyeon Choi, Jeong Won Jang, Gi Hyeon Seo, Bo Hyun Kim, Jong Young Choi","doi":"10.17998/jlc.2024.08.13","DOIUrl":"10.17998/jlc.2024.08.13","url":null,"abstract":"Backgrounds/aims: The treatment landscape for hepatocellular carcinoma (HCC) has significantly evolved over the past decade. We aimed to analyze trends in treatment patterns for HCC using a nationwide claims database from the Korean Health Insurance Review and Assessment Service.Methods: This retrospective population-based cohort study analyzed 171,002 newly diagnosed HCC patients between 2008 and 2022. Etiologies and treatment modalities were categorized based on the ICD-10 codes and insurance data.Results: The annual incidence decreased from 11,814 in 2008 to 10,443 in 2022. However, patients aged ≥70 increased noticeably, with those aged ≥80 rising from 3.8% in 2008 to 13.1% in 2022. From 2008 to 2022, the predominant cause of hepatitis B virus decreased from 68.9% to 59.7%, whereas nonalcoholic fatty liver disease increased from 8.9% to 15.8%. The initial treatment trends shifted: surgical resection and systemic therapy increased from 12.2% to 21.3% and from 0.2% to 9.6%, whereas transarterial therapy decreased from 49.9% to 36.6%. Best supportive care decreased from 31.7% to 21.3%. In the subgroup analysis, laparoscopic resection rate increased from 10.6% to 60.6% among the surgical resections. Sorafenib initially accounted for 100%, lenvatinib peaked at 36.5% in 2021, and atezolizumab-bevacizumab became the most widely used (63.1%) by 2022 among the systemic therapies.Conclusions: This study demonstrates the temporal changes in the treatment patterns of Korean HCC patients. Surgical resection, particularly laparoscopic liver resection, and systemic therapy has increased significantly. These changes may have been influenced by reimbursement policies and advances in clinical research.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"274-285"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142074857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The position of loco-regional therapy in the management of hepatocellular carcinoma with extrahepatic metastases. 局部区域疗法在治疗肝细胞癌肝外转移中的地位。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-08-29 DOI: 10.17998/jlc.2024.08.26

Beom Kyung Kim

引用次数: 0

Re-assessing the diagnostic value of the enhancing capsule in hepatocellular carcinoma imaging. 重新评估肝细胞癌成像中增强 "囊 "的诊断价值。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-05-08 DOI: 10.17998/jlc.2024.05.01

Jae Seok Bae, Jeong Min Lee, Bo Yun Hur, Jeongin Yoo, Sae-Jin Park

{"title":"Re-assessing the diagnostic value of the enhancing capsule in hepatocellular carcinoma imaging.","authors":"Jae Seok Bae, Jeong Min Lee, Bo Yun Hur, Jeongin Yoo, Sae-Jin Park","doi":"10.17998/jlc.2024.05.01","DOIUrl":"10.17998/jlc.2024.05.01","url":null,"abstract":"Backgrounds/aims: The enhancing capsule (EC) in hepatocellular carcinoma (HCC) diagnosis has received varying degrees of recognition across major guidelines. This study aimed to assess the diagnostic utility of EC in HCC detection.Methods: We retrospectively analyzed patients who underwent pre-surgical computed tomography (CT) and hepatobiliary agent-enhanced magnetic resonance imaging (HBA-MRI) between January 2016 and December 2019. A single hepatic tumor was confirmed based on the pathology of each patient. Three radiologists independently reviewed the images according to the Liver Imaging Reporting and Data System (LI-RADS) v2018 criteria and reached a consensus. Interobserver agreement for EC before reaching a consensus was quantified using Fleiss κ statistics. The impact of EC on the LI-RADS classification was assessed by comparing the positive predictive values for HCC detection in the presence and absence of EC.Results: In total, 237 patients (median age, 60 years; 184 men) with 237 observations were included. The interobserver agreement for EC detection was notably low for CT (κ=0.169) and HBA-MRI (κ=0.138). The presence of EC did not significantly alter the positive predictive value for HCC detection in LI-RADS category 5 observations on CT (94.1% [80/85] vs. 94.6% [88/93], P=0.886) or HBAMRI (95.7% [88/92] vs. 90.6% [77/85], P=0.178).Conclusions: The diagnostic value of EC in HCC diagnosis remains questionable, given its poor interobserver agreement and negligible impact on positive predictive values for HCC detection. This study challenges the emphasis on EC in certain diagnostic guidelines and suggests the need to re-evaluate its role in HCC imaging.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"206-216"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140878236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inter-reader agreement for LR-M imaging features: a premise for better imaging-based diagnosis in liver imaging. LR-M 成像特征的读片者间一致性：肝脏成像中更好的成像诊断前提。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-08-13 DOI: 10.17998/jlc.2024.08.06

Jaeseung Shin

引用次数: 0